



Gabinete de Promoção dos
Programa Quadro ID&I

Oportunidades de Financiamento na área da Saúde

Patrícia Calado

FCT
Fundação para a Ciência e a Tecnologia
MINISTÉRIO DA CIÊNCIA, TECNOLOGIA E ENSINO SUPERIOR

ANI
AGÊNCIA NACIONAL
DE INOVAÇÃO




Gabinete de Promoção dos Programa Quadro ID&I


FCT
Fundação para a Ciência e a Tecnologia
MINISTÉRIO DA CIÊNCIA, TECNOLOGIA E ENSINO SUPERIOR

ANI
AGÊNCIA NACIONAL
DE INOVAÇÃO

INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE NA EUROPA



DEVO CONCORRER AO H2020?



Pilar I
ERC
MSCA

Sim

Investigação fundamental ?

Não

Investigação aplicada, em consórcio ?

Desafio económico?

Preocupação da sociedade ?

Pilar II
Liderança industrial

Pilar III
Desafios Societais



COMO PROCURAR TÓPICOS DE INTERESSE?

Procurar no Participant Portal....


The screenshot shows the European Commission Research & Innovation Participant Portal. At the top, there is a navigation bar with 'HOME', 'FUNDING OPPORTUNITIES', 'HOW TO PARTICIPATE', 'EXPERTS', and 'SUPPORT'. A search bar labeled 'Search PP' is present. Below the navigation bar, the main content area displays search results for '145 Results'. A red box highlights the 'Search Topics' button in the left sidebar. Another red box highlights the 'free text search.' link in the search results area. A third red box highlights the 'EU Prize for Women Innovators' result, with an arrow pointing to the 'free text search.' link. The search results are filtered by 'Programme' (H2020, RFCS, COSME, 3rd HP, Cons Prog) and 'Status' (Forthcoming, Open, Closed). The results are sorted by '(Planned) opening date'. The first result is 'EU Prize for Women Innovators:WIP-01-2015' with call title 'EU Prize for Women Innovators' and call identifier 'H2020-WIPRIZE-2015'. The second result is 'Horizon Prize – Collaborative Spectrum Sharing:SpectrumPrize-01-2015' with call title 'Horizon Prize – Collaborative Sharing of Spectrum', status 'Forthcoming', and deadline '17-12-2015'.

Pesquisa por keywords....

...ou por texto livre

COMO PROCURAR TÓPICOS DE INTERESSE?

...ou estudar o Programa de Trabalhos!





OPORTUNIDADES DE FINANCIAMENTO

DESAFIO SOCIETAL 1



Better health for all

- 1 *Understanding health, wellbeing and disease*
- 2 *Preventing disease*
- 3 *Treating and managing disease*
- 4 *Active ageing and self-management of health*
- 5 *Methods and data*
- 6 *Health care provision and integrated care*



Orçamento (2014-2020): EUR 7.642 M

(9,7% do orçamento H2020)

OBJETIVOS PROGRAMA DE TRABALHOS DS1 2016-2017

Strategic orientation - “promoting healthy ageing and personalised healthcare”

Research priorities:

- Personalised medicine
- Rare diseases
- Human bio-monitoring
- Mental health
- Comparative effectiveness research
- Advanced technologies
- e/mHealth
- Robotics
- Patient empowerment
- Active and healthy ageing
- Data security
- Big data
- Valorisation
- Anti-microbial resistance
- Infectious diseases (incl. vaccines)
- Maternal and child health
- Silver economy




CARACTERÍSTICAS DO PROG. TRABALHOS 2016-2017

- Orçamento total: **~934 M€**
- Vários **tipos de instrumento**: acções de investigação e inovação em colaboração (RIAs), SME Instrument, prémios, financiamento inovador, cofinanciamento de programas (COFUND), ERA-NETs, Iniciativas de Programação Conjunta (JPIs) e acções de suporte e coordenação (CSAs).
- **Sinergias** com actividades no âmbito da **IMI2**, do **EDCTP**, do programa **AAL** e alinhamento com as prioridades da **EIP-AHA**.
- Investigação e inovação **responsáveis**, incluindo **aspectos éticos** e ciência sociais e humanidades (**SSH**).



PROGRAMA DE TRABALHOS DS1 2016-2017

- **Personalised Medicine (PM):**
21 tópicos (13 DG-RTD; 8 DG-CNECT)
- **Co-ordination Activities (HCO):**
16 tópicos (8 DG-RTD; 8 DG-CNECT)
- **Other actions: 11 tópicos**
- **Outubro de 2015:** publicação das *calls*.



TÓPICOS NO PROGRAMA DE TRABALHOS

Specific challenge: apresenta o contexto, o problema a resolver e explica a intervenção necessária.

Scope: delinea o problema, especifica o foco e os limites da potencial ação (não descreve ou limita a abordagem específica).

Expected impact: descreve os elementos chave do que é esperado conseguir em relação ao desafio.

PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities

Specific challenge: The development of new treatments is greatly facilitated by an improved understanding of the pathophysiology of diseases. There is therefore a need to address the current knowledge gaps in disease aetiology in order to support innovation in the development of evidence-based treatments. In this context, a better understanding of the mechanisms that are common to several diseases, in particular of those leading to co-morbidities, constitutes an important challenge.

Scope: Proposals should focus on the integration of pre-clinical and clinical studies for the identification of mechanisms common to several diseases. Proposals should assess and validate the relevance of these common mechanisms and of their biomarkers (where relevant) on the development of disease-specific pathophysiology, as well as their role in the development of co-morbidities in both males and females.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

- A better understanding of disease pathways and / or mechanisms common to a number of diseases
- New directions for clinical research for better disease prevention, health promotion, therapy development, and the management of co-morbidities

Type of action: Research and innovation actions



TIPOS DE ACÇÃO

Type of Action	Funding Rate	Aim
Research & Innovation Action (RIA)	100%	Collaborative research projects.
Innovation Action (IA)	70% (100% for non-profit organisations)	Produce plans & arrangements or designs for new, altered or improved products, processes or services.
Coordination & Support Action (CSA)	100%	Accompanying measures (standardisation, dissemination, policy dialogues etc.) no research.
SME Instrument	Phase 1: € 50K / project Phase 2: € 1-2.5M / project	Combination of demonstration activities (testing, prototyping, ...), market replication.

ESTUDOS CLÍNICOS


- Broad, inclusive definition of clinical studies (CS):

*A “clinical study” is ... any clinical research involving a substantial amount of work related to the **observation** of, **data collection** from, or **diagnostic or therapeutic intervention** on multiple or individual **patients/subjects**. It includes but is **not limited to clinical trials** in the sense of the EU Clinical Trials Directive (2001/20/EC).*


- CS are subject to the same legal provisions and guidance notes as other activities in H2020 (with the exception of “**unit costs**”)

OVERVIEW – CALL PERSONALISED MEDICINE


THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Understanding health, well-being and disease	SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system	RIA	RTD	13 Apr 2016
	SC1-PM-02-2017: New concepts in patient stratification	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-03–2017: Diagnostic characterisation of rare diseases	RIA	RTD	11 Apr 2017
	SC1-PM-04–2016: Networking and optimising the use of population and patient cohorts at EU level	RIA	RTD	13 Apr 2016
Preventing disease	SC1-PM-05–2016: The European Human Biomonitoring Initiative	COFUND (EJP)	RTD	13 Apr 2016
	SC1-PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases	RIA	RTD	13 Apr 2016
	SC1-PM-07–2017: Promoting mental health and well-being in the young	RIA	RTD	04 Oct 2016 (1st stage)
Treating and managing diseases	SC1-PM-08–2017: New therapies for rare diseases	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-09–2016: New therapies for chronic diseases	RIA	RTD	13 Apr 2016
	SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-11–2016-2017: Clinical research on regenerative medicine	RIA	RTD	13 Apr 2016
Active ageing and self-management of health	SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient	COFUND (PCP)	CNECT	16 Feb 2016
	SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing	COFUND (PPI)	CNECT	16 Feb 2016
	SC1-PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities	RIA	CNECT	19 Jan 2016
	SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age	RIA	CNECT	31 Jan 2017
Methods and data	SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products	RIA	CNECT	14 Mar 2017
	SC1-PM-17–2017: Personalised computer models and in-silico systems for well-being	RIA	CNECT	14 Mar 2017
	SC1-PM-18–2016: Big Data supporting Public Health policies	RIA	CNECT	16 Feb 2016
	SC1-PM-19–2017: PPI for uptake of standards for the exchange of digitalised healthcare records	COFUND (PPI)	CNECT	14 Mar 2017
	SC1-PM-20-2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector	RIA	RTD	11 Apr 2017
Health care provision and integrated care	SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries	RIA	RTD	13 Apr 2016



■ DG-RTD
■ DG-CNECT



■ Year 2016
■ Year 2017



■ RIA
■ COFUND - EJP
■ COFUND - PCP
■ COFUND - PPI

CALL PM “UNDERSTANDING HEALTH, WELL-BEING AND DISEASE”





THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Understanding health, well-being and disease	SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system CS	RIA	RTD	13 Apr 2016
	SC1-PM-02-2017: New concepts in patient stratification CS	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-03–2017: Diagnostic characterisation of rare diseases	RIA	RTD	11 Apr 2017
	SC1-PM-04–2016: Networking and optimising the use of population and patient cohorts at EU level	RIA	RTD	13 Apr 2016

CALL PM “PREVENTING DISEASE”


THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Preventing disease	SC1-PM-05–2016: The European Human Biomonitoring Initiative	COFUND (EJP)	RTD	13 Apr 2016
	SC1-PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases	RIA	RTD	13 Apr 2016
	SC1-PM-07–2017: Promoting mental health and well-being in the young	RIA	RTD	04 Oct 2016 (1st stage)



CALL PM “TREATING AND MANAGING DISEASES”

THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Treating and managing diseases	SC1-PM-08–2017: New therapies for rare diseases 	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-09–2016: New therapies for chronic diseases 	RIA	RTD	13 Apr 2016
	SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population 	RIA	RTD	04 Oct 2016 (1st stage)
	SC1-PM-11–2016-2017: Clinical research on regenerative medicine 	RIA	RTD	13 Apr 2016

CALL PM “ACTIVE AGEING AND SELF-MANAGEMENT OF HEALTH”

THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Active ageing and self-management of health	SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient	COFUND (PCP)	CNECT	16 Feb 2016
	SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing	COFUND (PPI)	CNECT	16 Feb 2016
	SC1-PM-14–2016: EU-Japan cooperation on N  Robotics based solutions for active and healthy ageing at home or in care facilities	RIA	CNECT	19 Jan 2016
	SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age	RIA	CNECT	31 Jan 2017

CALL PM – “METHODS AND DATA”

THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Methods and data	SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products	RIA	CNECT	14 Mar 2017
	SC1-PM-17–2017: Personalised computer models and in-silico systems for well-being	RIA	CNECT	14 Mar 2017
	SC1-PM-18–2016: Big Data supporting Public Health policies	RIA	CNECT	16 Feb 2016
	SC1-PM-19–2017: PPI for uptake of standards for the exchange of digitalised healthcare records	COFUND (PPI)	CNECT	14 Mar 2017
	SC1-PM-20-2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector	RIA	RTD	11 Apr 2017


CALL PM – “HEALTH CARE PROVISION AND INTEGRATED CARE”

THEME	TOPIC	TYPE OF ACTION	DG	DEADLINE
Health care provision and integrated care	SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries	RIA	RTD	13 Apr 2016




OVERVIEW – OTHER CO-ORDINATION ACTIVITIES


CALL	TYPE OF ACTION	DG	DEADLINE
SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results	CSA	RTD	13 Apr 2016
SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine	CSA	RTD	13 Apr 2016
SC1-HCO-03-2017: Implementing the Strategic Research Agenda on Personalised Medicine	ERA-NET Cofund	RTD	11 Apr 2017
SC1-HCO-04-2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance	CSA	RTD	13 Apr 2016
SC1-HCO-05-2016: Coordinating personalised medicine research	CSA	RTD	13 Apr 2016
SC1-HCO-06-2016: Towards an ERA-NET for building sustainable and resilient health system models	CSA	RTD	13 Apr 2016
SC1-HCO-07-2017: Global Alliance for Chronic Diseases (GACD)	RIA	RTD	11 Apr 2017
SC1-HCO-08-2017: Actions to bridge the divide in European health research and innovation	CSA	RTD	11 Apr 2017
SC1-HCO-09-2016: EU m-health hub including evidence for the integration of mHealth in the healthcare systems	CSA	CNECT	16 Feb 2016
SC1-HCO-10-2016: Support for Europe's leading Health ICT SMEs	CSA	CNECT	16 Feb 2016
SC1-HCO-11-2016: Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change	CSA	CNECT	16 Feb 2016
SC1-HCO-12-2016: Digital health literacy	CSA	CNECT	16 Feb 2016
SC1-HCO-13-2016: Healthcare workforce IT skills	CSA	CNECT	16 Feb 2016
SC1-HCO-14-2016: EU-US interoperability roadmap	CSA	CNECT	16 Feb 2016
SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment	CSA	CNECT	16 Feb 2016
SC1-HCO-16-2016: Standardisation needs in the field of ICT for Active and Healthy Ageing	CSA	CNECT	16 Feb 2016



■ DG-RTD
■ DG-CNECT



■ Year 2016
■ Year 2017



■ CSA
■ ERA-NET
■ RIA

OTHER CO-ORDINATION ACTIVITIES (I)

CALL	TYPE OF ACTION	DG	DEADLINE
SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results	CSA	RTD	13 Apr 2016
SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine	CSA	RTD	13 Apr 2016
SC1-HCO-03–2017: Implementing the Strategic Research Agenda on Personalised Medicine	ERA-NET Cofund	RTD	11 Apr 2017
SC1-HCO-04–2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance	CSA	RTD	13 Apr 2016
SC1-HCO-05–2016: Coordinating personalised medicine research	CSA	RTD	13 Apr 2016
SC1-HCO-06–2016: Towards an ERA-NET for building sustainable and resilient health system models	CSA	RTD	13 Apr 2016
SC1-HCO-07–2017: Global Alliance for Chronic Diseases (GACD)	RIA	RTD	11 Apr 2017
SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation	CSA	RTD	11 Apr 2017



OTHER CO-ORDINATION ACTIVITIES (II)


CALL	TYPE OF ACTION	DG	DEADLINE
SC1-HCO-09–2016: EU m-health hub including evidence for the integration of mHealth in the healthcare systems	CSA	CNECT	16 Feb 2016
SC1-HCO-10–2016: Support for Europe’s leading Health ICT SMEs	CSA	CNECT	16 Feb 2016
SC1-HCO-11–2016: Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change	CSA	CNECT	16 Feb 2016
SC1-HCO-12–2016: Digital health literacy	CSA	CNECT	16 Feb 2016
SC1-HCO-13–2016: Healthcare workforce IT skills	CSA	CNECT	16 Feb 2016
SC1-HCO-14–2016: EU-US interoperability roadmap	CSA	CNECT	16 Feb 2016
SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment	CSA	CNECT	16 Feb 2016
SC1-HCO-16-2016: Standardisation needs in the field of ICT for Active and Healthy Ageing	CSA	CNECT	16 Feb 2016

OVERVIEW – TÓPICOS SAÚDE NO SME INSTRUMENT

Call H2020-SMEInst-2016-2017

SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector

SMEInst-06-2016-2017: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well



Continuously open call H2020-SMEInst-2016-2017, Horizon 2020 Work Programme Part – Innovation in SMEs



NCPs Saúde:

Saúde
IMI



Patricia Calado

✉ patricia.calado@gppq.pt

☎ +351 91 183 64 53



OPORTUNIDADES DE FINANCIAMENTO DESAFIO SOCIETAL 2



5 grandes atividades no Programa Específico do DS2



**Agricultura
e silvicultura**

**Sector Agro-
alimentar**

**Aquicultura e
pescas**

**Bioindústrias
e
bioeconomia**

**Investigação
marinha e
marítima**



<http://ec.europa.eu/programmes/horizon2020/en/h2020-section/food-security-sustainable-agriculture-and-forestry-marine-maritime-and-inland-water>



Gabinete de Promoção dos Programa Quadro ID&I
Gabinete de Promoção dos Programa Quadro ID&I



Desafio Societal 2 → The ‘Sustainable Food Security’ focus area (WP 2016/17)


2016: 180,5 M€ | 2017: 251 M€

SFS - Call “Sustainable Food Security”

- *More resilient and resource efficient value chains*
- *Environment-smart and climate-smart primary production*
- *A competitive food industry*
- *Healthy and safe foods and diets for all*

As atividades propostas nesta *call* pretendem **desenvolver sistemas de produção (aquáticos/terrestres) competitivos e c/ máxima eficiência de recursos**, havendo neste *WP* uma maior ênfase na resiliência da produção primária e nas indústrias associadas e sido dada maior visibilidade ao **consumo sustentável e saudável e aos estilos de vida**.

Esta *Focus Area* é particularmente relevante para a cooperação internacional, em particular: região Mediterrânica. África, China, Sudoeste Asiático.



17 Fev2016 | 14 Fev 2017
two-stage topics

'Sustainable Food Security' call (SFS)

2016 2017

SAFE AND HEALTHY DIETS AND SUSTAINABLE CONSUMPTION

SFS-37: The impact of consumer practices in food safety: risks and mitigation strategies (RIA, 9,5M€)

X

SFS-38: Impulsivity and compulsivity and the link to nutrition, lifestyle and the socio-economic environment (RIA, 12M€)

X

SFS-39: How to tackle the childhood obesity epidemic (RIA, 10M€)

X

SFS-40: Sweeteners and sweetness enhancers (RIA, 9M€)

X



Desafio Societal 2 → *The 'Blue Growth' focus area (WP 2016/17)*

2016: 82 M€ | 2017: 47 M€

BG - Call "Blue Growth"

- *Innovation for emerging BG activities*
- *Healthy oceans and seas for healthy people*
- *Strengthening the European ocean observing, surveying and monitoring capability*

Esta *Focus Area* pretende apoiar as tecnologias para o nível de desenvolvimento que permita aplicações comerciais e reforçar a capacidade de observação e monitorização

Contribui p/ implementação da Estratégia de Cooperação Internacional em I&I e outros compromissos políticos da UE (*Galway Statement, Blue Med initiative*, cooperação c/ Sudoeste Asiático em aquacultura)

Integração de contribuições de outras áreas do H2020: DS3 'Energia', DS4 'Transportes', e DS5 'Ação climática'

http://ec.europa.eu/maritimeaffairs/policy/blue_growth/

PILLAR 2: *Healthy oceans and seas for healthy people*

→ O objetivo é explorar a **interação entre os oceanos e a saúde humana**



14 Fev2017
One-stage topics

Healthy oceans and seas for healthy people

BG-6: Interaction between humans, oceans and seas: a strategic approach towards healthcare and wellbeing (CSA, 2M€)

BG-8: Innovative sustainable solutions for improving the safety and dietary properties of seafood (IA, 7M€)

	2016	2017
BG-6: Interaction between humans, oceans and seas: a strategic approach towards healthcare and wellbeing (CSA, 2M€)		X
BG-8: Innovative sustainable solutions for improving the safety and dietary properties of seafood (IA, 7M€)		X

NCP Bioeconomia:

Bio Economia

BBI

Biotechnologia



Maria João Fernandes

🏠 GPPQ

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

✉ mariajoao.fernandes@fct.pt

☎ +351 91 841 79 20



OPORTUNIDADES DE FINANCIAMENTO NMPB



Gabinete de Promoção dos Programa Quadro ID&I



1

Materiais avançados e nanotecnologia para **produtos de elevado valor acrescentado e indústria de processos**

2

Materiais Avançados e Nanotecnologias para os **Cuidados de Saúde**

3

Materiais Avançados e Nanotecnologias para a **Energia**

4

Eco-design e novos **modelos de negócio sustentáveis**

5

Biotecnologia

6

Modelação para o desenvolvimento de nanotecnologias e materiais avançados

7

Avaliação e Gestão do risco das nanotecnologias, materiais avançados e biotecnologias

8

Governância inovadora e responsável de tecnologias facilitadoras novas e convergentes

Materiais Avançados e Nanotecnologias para os Cuidados de Saúde

- As atividades da nanomedicina objetivam a **redução dos processos de investigação**, desenvolvimento e aprovação **regulamentar**, reduzindo os custos associados e promovendo produtos seguros e eficazes respondendo às necessidades de melhoria dos cuidados de saúde.
- Do ponto de vista operacional, a nanomedicina deve focar-se na tradução do *“lab-to-bedside”*

biomateriais para produtos da engenharia de tecidos

nanossistemas e nanodispositivos para entrega controlada de fármacos

diagnóstico e imagiologia molecular

Etc.

As atividades serão posicionados em relação às atividades de *Societal Challenge 'Health, demographic change and well-being' (including Micro-Nano-Biosystems and e-Health)*, the *European Research Council (Frontier Research)*, *Research Infrastructures*, envolvimento da [European Medicines Agency](#), e outros.

Nanotecnologia e materiais avançados para Cuidados de Saúde mais eficazes

Tópico	Ação	Cont. EC/proj
NMBP-09-2016: Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System	RIA	5 – 8 M€
NMBP-10-2016: Nanoformulation of biologicals	RIA	5 – 6 M€
NMBP-12-2017: Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices	RIA	5 – 8 M€
NMBP-14-2017: Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials	RIA	5 – 8 M€ Apenas 1 projeto financiado
NMBP-15-2017: Nanotechnologies for imaging cellular transplants and regenerative processes in vivo	RIA	5 – 7 M€
NMBP-13-2017: Cross-cutting KETs for diagnostics at the point-of-care	RIA	3 – 5 M€
NMBP-16-2017: Mobilising the European nano-biomedical ecosystem	CSA	1-2 M€



NCPs NMP:

NMP+B

Apoio a PME
Fast Track



Marta Candeias

🏠 GPPQ

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

✉ marta.candeias@fct.pt

☎ +351 93 200 38 41

NMP+B

RFCS



Sofia Azevedo

🏠 GPPQ

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

✉ sofia.azevedo@fct.pt


☎ +351 93 929 09 20



OPORTUNIDADES DE FINANCIAMENTO FET



Pilar I – FET: Três esquemas de financiamento



FET-Open

Early Ideas
Uncorrelated
Research projects

FET Proactive

Exploration and Incubation
Topical clusters
of research projects

FET Flagships

Large-Scale Partnering Initiatives
Common research
agendas

Call FET Proactive – boosting emerging technologies
FETPROACT 1 – 2016: FET-Proactiv: emerging themes and con

Graphene
Human Brain Project

Scope:

- 2: Biotech for better life**
- c) Intra- and inter-cell bio-nano-chem technologies
- d) Bio-electronic medicines and therapies adaptive nerve
- e) Cognitive neuron technologies

NCPs FET:

FET | ICT

ECSEL

NCP para a Administração Pública



Elisabete Pires

✉ elisabete.pires@gppq.pt

☎ +351 93 586 72 08

FET

ICT

Energia



Eunice Ribeiro

✉ eunice.ribeiro@gppq.pt

☎ +351 93 929 09 23



INICIATIVAS ESTRATÉGICAS SAÚDE





Innovative Medicines Initiative 2
www.imi.europa.eu



European Innovation Partnership on Active and Healthy Ageing
<https://webgate.ec.europa.eu/eipaha>



Elisabete Pires
elisabete.pires@fct.pt

Active and Assisted Living 2
www.aal-europe.eu



Ricardo Pereira
ricardo.pereira@fct.pt

European & Developing Countries Clinical Trials Partnership (EDCTP2)
www.edctp.org

INICIATIVA DOS MEDICAMENTOS INOVADORES (IMI2)

- Iniciativa Tecnológica Conjunta entre a **União Europeia** e a **EFPIA**
- Objectivos do IMI2 com base na Strategic Research Agenda (SRA):

1

A 30% better success rate in **clinical trials of priority medicines** identified by the WHO;

2

Clinical proof of concept in **immunological, respiratory, neurological and neurodegenerative diseases** in just five years;

3

New and approved **diagnostic markers** for four of these diseases and at least two **new medicines** which could either be new **antibiotics** or new therapies for **Alzheimer's disease**.

ORÇAMENTO TOTAL IMI2 (2014-2024): 3.276 M€

(1.638 M€ H2020 + 1.425 M€ EFPIA (*in kind*) + 213 M€ indústrias das ciências da vida)



IMI2 – 5TH CALL FOR PROPOSALS (RIA, 2-stage)

DEADLINE 13 October 2015

- IMI2-2015-05-01: **Patient perspective** elicitation of medicinal products from development through the entire lifecycle. **Risk assessments** by Regulators and Health Technology Assessment (HTA) (29.8 M€)
- IMI2-2015-05-02: **Diabetic Kidney Disease** Biomarkers (DKD-BM) (29.8 M€)
- IMI2-2015-05-03: **Inflammation** and **AD**: modulating microglia function – focussing on **TREM2** and **CD33** (17.2 M€)
- IMI2-2015-05-04: Understanding the role of **amyloid biomarkers** in the current and future diagnosis and management of patients across the spectrum of **cognitive impairment** (from predementia to dementia) (24 M€)
- IMI2-2015-05-05: Evolving models of **patient engagement and access** for earlier identification of **Alzheimer's** disease: Phased expansion study (4.08 M€)
- IMI2-2015-05-06 : **ApoE** biology to validated **Alzheimer's** disease targets (5.28 M€)



IMI2 – 6TH CALL FOR PROPOSALS (RIA, 2-stage)

DEADLINE 12 January 2016

- **Topic 1:** Development of a quantitative **system**
- **Topic 2:** Establishing impact of **RSV infection**, resultant **disease and public health** **approach** to reducing the consequences (RIA)
- **Topic 3:** Under the IMI programme **Big Data for Better Outcomes** (CSA)
- **Topic 4:** Real World Outcomes Across the **AD Spectrum** (ROADS) to **Better Care** (RIA)
- **Topic 5:** Development of an outcomes focused informatics platform to **empower policy makers** and **clinicians** to optimize **care for patients with hematologic malignancies** (RIA)





Innovative Medicines Initiative 2
www.imi.europa.eu



European Innovation Partnership on Active
and Healthy Ageing
<https://webgate.ec.europa.eu/eipaha>



Elisabete Pires
elisabete.pires@fct.pt

Active and Assisted Living 2
www.aal-europe.eu



Ricardo Pereira
ricardo.pereira@fct.pt


European & Developing Countries Clinical
Trials Partnership (EDCTP2)
www.edctp.org

EIP ON ACTIVE AND HEALTHY AGEING

Cooperação entre a Comissão Europeia e os países da UE, as regiões, a indústria, os profissionais do setor social e do setor da saúde e as organizações representativas dos idosos e dos doentes



The Marketplace: plataforma *online* para adesão, discussão e partilha de informação



❖ Não é um mecanismo legal nem de financiamento da UE

NCPs Saúde:

Saúde
IMI



Patricia Calado

✉ patricia.calado@gppq.pt

☎ +351 91 183 64 53

COMO COMEÇAR?

- Ideia **clara** para um projeto
- Consistente com o **tópico** do programa de trabalhos
- **Inovadora** e com potencial de **exploração**
- Para além do **estado-da-arte**
- Dimensão **Europeia!**



FERRAMENTAS DE PROCURA DE PARCEIROS EU E PT

Congressos/conferências



Horizon 2020 Health Open Info Days

Open Info Day - Horizon 2020 'Health, Geographic change and wellbeing'
Centre Albert Descartes, rue Princesse, 64, 1050 Brussels, Belgium
Friday 14 November 2014

Infodays UE



Ferramentas virtuais



Redes profissionais



Projetos financiados
(>1000 entre 2007-2013)

H2020 Health European Brokerage Event
Partnering for PHC 2015 calls



Gabinete de Promoção dos Programa Quadro ID&I



PROPOSTAS H2020 – ABORDAGEM INTEGRADA



Painel de
Avaliação

- soluções para o problema
- inovadora
- viável nas metas propostas
- competências e complementaridade no consórcio
- dimensão Europeia
- bem orçamentada
- estrutura de gestão adequada à dimensão do consórcio e complexidade da proposta



Escolher um acrónimo que faça sentido e título apelativo (baseado no impacto)

“Título = SLOGAN | Acrónimo – Brand”

PLACES: Platform of Local Authorities and Communicators Engaged in Science





Make a
good first
impression



**Investir num *abstract* e num *pitch*
apelativos, que reforcem a inovação e o
impacto do projecto**



Investir numa apresentação eficaz e visualmente atraente

Apresente factos e números

Utilize gráficos, esquemas e tabelas
Parágrafos curtos, 'bullets', itálico, sublinhado

Usar e abusar do acrónimo do projeto



Flawless english

editar editar editar



Proposta convincente


Consórcio sólido

Ideia



CONCURSO PORTUGAL 2020

- Elegíveis despesas realizadas **depois da candidatura estar submetida** no âmbito do PT2020
- **Todas** as regiões **NUTS II** do Continente (Norte, Centro, Lisboa, Alentejo e Algarve)
- **Empresas** de qualquer natureza e sob qualquer forma jurídica e as **Entidades não empresariais do Sistema de I&I**
- **Plano** de participação em programas do Horizonte 2020 para um **período de um ou dois anos**



GPPQ – Gabinete de Promoção do Programa-Quadro

www.gppq.pt/h2020/

Verifique o calendário das sessões de divulgação e workshops sobre escrita de propostas



http://www.gppq.pt/h2020/contactos_ncp.php



Gabinete de Promoção dos Programa Quadro ID&I

FCT
Fundação para a Ciência e a Tecnologia
MINISTÉRIO DA CIÊNCIA, TECNOLOGIA E ENSINO SUPERIOR



AGÊNCIA NACIONAL
DE INOVAÇÃO